Silence Therapeutics CFO to Join H.C. Wainwright BioConnect Investor Conference
Event summary
- Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 19, 2026, at 2:00 p.m. ET.
- The live webcast will be accessible via the Investors section of Silence Therapeutics' website.
- An archived replay of the webcast will be available post-conference.
The big picture
Silence Therapeutics' participation in the H.C. Wainwright BioConnect Investor Conference underscores its focus on engaging with investors to discuss its innovative siRNA therapies. The event provides a platform for the company to showcase its mRNAi GOLD™ platform and its growing pipeline targeting high unmet medical needs. This engagement is critical as the biotech sector continues to evolve, with increasing emphasis on precision medicine and novel therapeutic approaches.
What we're watching
- Pipeline Progress
- How Silence Therapeutics will highlight advancements in its siRNA product pipeline during the conference.
- Investor Sentiment
- Whether the presentation will influence investor confidence in the company's clinical-stage developments.
- Strategic Direction
- The pace at which Silence Therapeutics will outline its long-term strategy in rare and common diseases.
Related topics